Can I take Suboxone (buprenorphine/naloxone) daily while using methamphetamine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can You Take Suboxone Daily While Using Methamphetamine?

Yes, you can and should continue taking Suboxone (buprenorphine/naloxone) daily even if you are using methamphetamine, because discontinuing buprenorphine precipitates opioid withdrawal and dramatically increases your risk of relapse to more dangerous opioids and overdose death. 1

Why Suboxone Should Be Continued

  • Buprenorphine maintenance therapy saves lives by preventing relapse to illicit opioids (such as heroin or fentanyl), which carry far higher overdose mortality than methamphetamine use. 1

  • There is no pharmacologic contraindication to taking buprenorphine while using stimulants like methamphetamine—the two drug classes act on completely different receptor systems (opioid receptors versus dopamine/norepinephrine systems). 2

  • Stopping buprenorphine to address methamphetamine use is counterproductive because it removes the protective effect against opioid relapse without treating the stimulant problem. 1

Managing Concurrent Stimulant Use

  • Address methamphetamine use separately through behavioral interventions (cognitive-behavioral therapy, contingency management) and psychosocial support, while maintaining the buprenorphine regimen. 1

  • Screen for and treat co-occurring psychiatric conditions (depression, anxiety, ADHD) that may be driving methamphetamine use, as these are common in patients with polysubstance use. 1

  • Increase monitoring frequency with weekly or biweekly visits during active methamphetamine use to provide closer clinical oversight and harm-reduction counseling. 1

Safety Considerations Specific to This Combination

  • QT-interval prolongation risk: Both buprenorphine and methamphetamine can prolong the QT interval; obtain a baseline ECG and avoid other QT-prolonging medications (certain antipsychotics, antibiotics, antiarrhythmics). 2, 3

  • Cardiovascular monitoring: Methamphetamine causes tachycardia and hypertension; check vital signs at each visit and refer for cardiology evaluation if chest pain, palpitations, or syncope occur. 2

  • Avoid serotonergic combinations: Methamphetamine has serotonergic activity; combining it with buprenorphine plus other serotonergic agents (SSRIs, SNRIs, tramadol) raises the theoretical risk of serotonin syndrome—monitor for agitation, hyperthermia, tremor, and hyperreflexia. 2

Standard Buprenorphine Dosing Remains Unchanged

  • Maintain the standard 16 mg daily dose (range 4–24 mg) that was effective before methamphetamine use began; do not reduce the buprenorphine dose in response to stimulant use. 1, 4

  • Once-daily dosing is preferred over split dosing (e.g., 8 mg twice daily), as once-daily administration is associated with fewer opioid relapses and more negative urine drug screens. 5

Harm-Reduction Measures

  • Provide take-home naloxone kits at every visit, because polysubstance use (especially if opioids are reintroduced) increases overdose risk. 1

  • Offer hepatitis C and HIV screening routinely, as injection methamphetamine use and sexual risk behaviors associated with stimulant use elevate transmission risk. 1

  • Counsel on safer use practices if the patient continues methamphetamine use (avoid injection, use clean supplies, stay hydrated, avoid mixing with other depressants). 1

Common Pitfalls to Avoid

  • Do not discontinue or taper buprenorphine in an attempt to "simplify" treatment or because the patient is using other substances—this removes the life-saving protection against opioid overdose. 1

  • Do not withhold buprenorphine refills as punishment for positive methamphetamine urine screens; this punitive approach drives patients away from care and increases mortality. 1

  • Do not assume methamphetamine use indicates buprenorphine treatment failure—polysubstance use is common, and buprenorphine specifically treats opioid use disorder, not stimulant use disorder. 1

References

Guideline

Medications for Managing Opioid Withdrawal

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Concurrent Use of Sublocade and Suboxone – Evidence‑Based Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Buprenorphine Prescribing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.